Trial Profile
A First-in-Human Phase I Study of Intravesical sEphB4-HSA in Patients With "BCG-Unresponsive" Bladder Carcinoma In Situ (CIS), Completely Resected High Grade Ta/T1, to Establish the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs SEphB4-HSA (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; First in man
- 23 Jun 2023 Status changed from not yet recruiting to suspended (Due to budget issues).
- 24 May 2023 Planned End Date changed from 3 Apr 2025 to 1 Aug 2025.
- 24 May 2023 Planned primary completion date changed from 3 Apr 2024 to 1 Aug 2024.